Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
18:15:56 EDT Fri 26 Apr 2024
Enter Symbol
or Name
USA
CA



Q:KRTX - KARUNA THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
KRTX - QHALTED329.83    329.99  158.375Mar 15Feb 2215 min RT 2¢

Recent Trades - All 0 today
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-02-22 06:30U:KRTXNews ReleaseKaruna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update
2023-12-22 07:05U:KRTXNews ReleaseBristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
2023-12-14 18:30U:KRTXNews ReleaseKaruna Therapeutics Announces The Lancet Publication of Data from Phase 3 EMERGENT-2 Trial Evaluating KarXT in Schizophrenia
2023-11-29 10:17U:KRTXNews ReleasePureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
2023-11-29 06:30U:KRTXNews ReleaseKaruna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
2023-11-16 16:01U:KRTXNews ReleaseKaruna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
2023-11-02 06:30U:KRTXNews ReleaseKaruna Therapeutics Reports Third Quarter 2023 Financial Results and Provides General Business Updates
2023-11-01 06:45U:KRTXNews ReleaseKaruna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2023 Neuroscience Education Institute Congress
2023-11-01 06:30U:KRTXNews ReleaseKaruna Therapeutics to Present at Upcoming Investor Conferences
2023-10-19 06:30U:KRTXNews ReleaseKaruna Therapeutics to Announce Third Quarter 2023 Financial Results and Provide General Business Update on Thursday, November 2, 2023
2023-10-04 06:30U:KRTXNews ReleaseKaruna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 36th European College of Neuropsychopharmacology (ECNP) Congress
2023-09-28 06:30U:KRTXNews ReleaseKaruna Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KarXT for the Treatment of Schizophrenia
2023-08-30 06:30U:KRTXNews ReleaseKaruna Therapeutics to Present at Upcoming Investor Conferences
2023-08-03 06:32U:KRTXNews ReleaseKaruna Therapeutics Reports Second Quarter 2023 Financial Results and Provides General Business Updates
2023-08-03 06:30U:KRTXNews ReleaseKaruna Therapeutics Announces Leadership Appointments
2023-07-20 06:30U:KRTXNews ReleaseKaruna Therapeutics to Announce Second Quarter 2023 Financial Results and Provide General Business Update on Thursday, August 3, 2023
2023-05-30 06:30U:KRTXNews ReleaseKaruna Therapeutics to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
2023-05-22 06:30U:KRTXNews ReleaseKaruna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the American Society of Clinical Psychopharmacology Annual Meeting
2023-05-04 06:30U:KRTXNews ReleaseKaruna Therapeutics Reports First Quarter 2023 Financial Results and Provides General Business Updates